Modified metal prosthesis material and preparation method thereof, and artificial prosthesis

By covalently linking osteolysis inhibitory proteins to the metal prosthesis material, the loosening problem caused by osteolysis of the metal prosthesis is solved, achieving long-term stability and extended service life of the prosthesis.

CN117398522BActive Publication Date: 2024-11-26SHENZHEN UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202311308988.3
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2023-10-10
Publication Date
2024-11-26
Estimated Expiration
2043-10-10

AI Technical Summary

Technical Problem

Existing metal prosthesis materials can become loose due to osteolysis during use, leading to frequent revision surgeries, which affects patients' health and financial burden.

Method used

Therapeutic proteins that inhibit osteolysis, such as interleukin-4, are covalently linked to metallic prosthetic materials. Vinyl sulfone groups are linked to the metal carrier through chemical functionalization, and then combined with the therapeutic protein to form modified metallic prosthetic materials.

Benefits of technology

Modified metallic prosthesis materials promote osseointegration in the early post-implantation period, inhibit osteoclast activity, slowly release therapeutic agents, prolong prosthesis lifespan, and reduce the risk of loosening.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN117398522B_ABST
    Figure CN117398522B_ABST
Patent Text Reader

Abstract

The present invention discloses a modified metal prosthesis material, a preparation method thereof, and an artificial prosthesis comprising the modified metal prosthesis material. The modified metal prosthesis material comprises a metal carrier, a vinyl sulfone group covalently connected to the metal carrier, and a therapeutic protein covalently connected to the vinyl sulfone group; the material of the metal carrier is titanium or a titanium alloy, and the therapeutic protein has an inhibitory effect on bone dissolution around the prosthesis. The modified metal prosthesis material of the present invention covalently connects the therapeutic protein that has an inhibitory effect on bone dissolution to the metal carrier, so that the artificial prosthesis made of the modified metal prosthesis material can inhibit the activity of osteoclasts when in the human body, and in the subsequent use process, slowly and continuously releases the therapeutic agent, thereby achieving the effect of inhibiting bone dissolution, avoiding loosening of the artificial prosthesis, and extending the service life of the artificial prosthesis.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the technical field of metal prosthesis materials, and in particular to a modified metal prosthesis material and a preparation method thereof, and an artificial prosthesis. Background Art

[0002] Artificial joint replacement is a very effective means of treating end-stage joint diseases and femoral and cervical fractures in the elderly, and can significantly improve the quality of life of patients. Every year, about 1.5 million patients with joint dysfunction caused by degenerative and inflammatory arthritis undergo artificial joint replacement. After decades of efforts, artificial prostheses have made great progress in material modification, fixation methods, and mechanical design.

[0003] Titanium and its alloys have excellent mechanical properties (good strength and low elastic modulus), biocompatibility, good corrosion resistance caused by a stable oxide layer, good strength and low density. Due to these excellent properties, titanium and its alloys have become the preferred materials for manufacturing artificial prostheses.

[0004] However, the service life of artificial metal prostheses is always very limited. As the service life of artificial prostheses increases, the probability of artificial prosthesis loosening also increases. According to statistics, about 10% of patients need artificial joint revision surgery within 15 years after the initial artificial joint prosthesis replacement. As the age of patients becomes younger and the number of cases gradually increases, the number of cases requiring artificial prosthesis revision surgery due to aseptic loosening of artificial prostheses will gradually increase. In some large medical centers, the number of revision surgery cases has reached about 20% of total hip replacement surgeries in the same period. Studies have shown that the incidence of aseptic loosening is 13% on the femoral side and 34% on the acetabular side. Since the efficacy of revision surgery is lower than that of the initial surgery, the surgery is traumatic and expensive, which brings great physical and mental pain and economic pressure to patients.

[0005] It is currently believed that the main cause of artificial prosthesis loosening is osteolysis at the prosthesis site. Osteolysis refers to bone loss caused by a series of biological reactions induced by wear particles at the prosthesis-bone interface. Artificial prosthesis movement and interface micro-motion inevitably produce a large number of wear particles between the interfaces. These wear particles migrate in the joint space with the synovial fluid, diffuse into the periprosthetic tissue, and interact with the cells around the prosthesis. After being stimulated by wear particles, these cells can secrete a variety of mediators and cytokines that promote bone absorption, such as prostaglandin 2, tumor necrosis factor-α, interleukin 1, etc. These mediators and cytokines can act alone or in combination to promote the differentiation and maturation of osteoclasts, and activate osteoclasts, which then cause the absorption and dissolution of bone around the prosthesis by osteoclasts, ultimately leading to artificial prosthesis loosening. Summary of the invention

[0006] Based on this, it is necessary to provide a modified metal prosthesis material that can solve the above problems.

[0007] In addition, it is also necessary to provide a method for preparing the above-mentioned modified metal prosthesis material and an artificial prosthesis comprising the modified metal prosthesis material.

[0008] A modified metal prosthesis material comprises a metal carrier, a vinyl sulfone group covalently linked to the metal carrier, and a therapeutic protein covalently linked to the vinyl sulfone group;

[0009] The material of the metal carrier is titanium or titanium alloy, and the therapeutic protein has an inhibitory effect on periprosthetic bone dissolution.

[0010] In one embodiment, the therapeutic protein is covalently linked to the vinyl sulfone group via an amino acid residue.

[0011] In one embodiment, the amino acid residue includes at least one of -Cys, -Lys and -Hsi.

[0012] In one embodiment, the metal carrier is modified with -OH, and the vinyl sulfone group is covalently bonded to -OH, thereby achieving covalent connection with the metal carrier.

[0013] In one embodiment, the therapeutic protein is selected from at least one of interleukin-1RA, interleukin-4, interleukin-6, interleukin-10, interleukin-13 and transforming growth factor-β1.

[0014] In one embodiment, the modified metal prosthesis is made of titanium or titanium alloy.

[0015] A method for preparing the modified metal prosthesis material comprises the following steps:

[0016] Providing a metal carrier, and performing chemical functionalization treatment on the metal carrier, wherein the material of the metal carrier is titanium or a titanium alloy;

[0017] Dispersing the chemically functionalized metal carrier into an organic solvent, then adding vinyl sulfone and a catalyst, reacting them fully under stirring, and obtaining a semi-finished product after separation, wherein the semi-finished product includes the metal carrier and a vinyl sulfone group covalently connected to the metal carrier;

[0018] The semi-finished product is dispersed in an aqueous solvent, a therapeutic protein is added, and the mixture is fully reacted under stirring. After separation, the desired modified metal prosthesis material is obtained, wherein the modified prosthesis material includes the metal carrier, the vinyl sulfone group covalently linked to the metal carrier, and the therapeutic protein covalently linked to the vinyl sulfone group, and the therapeutic protein has an inhibitory effect on periprosthetic bone dissolution.

[0019] In one embodiment, the operation of chemically functionalizing the metal support is: placing the metal support in a 0.1M to 5M NaOH solution and treating it at 50° C. to 80° C. for 12 h to 48 h.

[0020] In one embodiment, the chemically functionalized metal support is dispersed in an organic solvent, and then vinyl sulfone and a catalyst are added, wherein the ratio of the chemically functionalized metal support, the organic solvent, the vinyl sulfone and the catalyst is 0.05 g to 0.5 g: 2.5 mL to 10 mL: 0.25 mL to 2.5 mL: 0.05 mmol to 0.5 mmol;

[0021] The organic solvent is acetonitrile, and the catalyst is triphenylphosphine;

[0022] Dispersing the semi-finished product in an aqueous solvent and adding the therapeutic protein, the ratio of the semi-finished product to the therapeutic protein is 0.05 g to 0.5 g: 25 μg to 250 μg;

[0023] The aqueous solvent is phosphate buffer.

[0024] An artificial prosthesis comprises the above-mentioned modified metal prosthesis material.

[0025] The modified metal prosthesis material of the present invention covalently links a therapeutic protein that has an inhibitory effect on bone dissolution to a metal carrier, so that the artificial prosthesis made of the modified prosthetic material can inhibit macrophage activation, promote bone integration, and inhibit osteoclast activity and bone dissolution in the early stage after implantation, and in the subsequent use process, slowly and continuously release the therapeutic agent, thereby achieving the effect of inhibiting bone dissolution, avoiding loosening of the artificial metal prosthesis, and extending the service life of the artificial prosthesis.

[0026] In combination with the specific embodiments, in a particular embodiment, when the therapeutic protein is interleukin-4, the modified metal prosthesis material can play a role in the early implant bone integration process by regulating the macrophage polarization phenomenon, inhibiting the production of osteoclasts and thus inhibiting periprosthetic bone dissolution. BRIEF DESCRIPTION OF THE DRAWINGS

[0027] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments or the description of the prior art will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.

[0028] in:

[0029] Figure 1 The present invention is a flow chart of a method for preparing a modified metal prosthetic material according to one embodiment.

[0030] Figure 2 For Figure 1 Schematic diagram of the preparation method of the modified metal prosthetic material shown.

[0031] Figure 3 The graph is a comparison of the results of TRAP staining for the osteoclast differentiation marker after treating bone marrow-derived macrophages with the Ti group in Test Example 1 (untreated titanium particles, positive control), the Ti+IL4 group (untreated titanium particles + cytokine IL4, negative control group), the modified prosthetic material Ti-IL4-25 prepared in Example 1, the modified prosthetic material Ti-IL4-125 prepared in Example 2, and the modified prosthetic material Ti-IL4-500 prepared in Example 3, respectively.

[0032] Figure 4 This is a comparison chart of the osteoclast differentiation marker CTSK staining results after treating bone marrow-derived macrophages with the Ti group in Test Example 1 (untreated titanium particles, positive control), the Ti+IL4 group (untreated titanium particles + cytokine IL4, negative control group), the modified prosthetic material Ti-IL4-25 prepared in Example 1, the modified prosthetic material Ti-IL4-125 prepared in Example 2, and the modified prosthetic material Ti-IL4-500 prepared in Example 3, respectively.

[0033] Figure 5 This is a graph showing the quantitative results of the activity of the osteoclast differentiation marker TRAP after bone marrow-derived macrophages were treated with the Ti group in Test Example 1 (untreated titanium particles, positive control), the Ti+IL4 group (untreated titanium particles + cytokine IL4, negative control group), the modified prosthetic material Ti-IL4-25 prepared in Example 1, the modified prosthetic material Ti-IL4-125 prepared in Example 2, and the modified prosthetic material Ti-IL4-500 prepared in Example 3.

[0034] Figure 6 CT reconstruction images of the untreated titanium particle group and the modified prosthetic material Ti-IL4-500 prepared in Example 3 under the osteolysis model.

[0035] Figure 7 This is a graph showing the bone density analysis results of the untreated titanium particle group and the modified prosthetic material Ti-IL4-500 prepared in Example 3 under the osteolysis model.

[0036] Figure 8This is a graph showing the bone volume fraction analysis results under the osteolysis model for the untreated titanium particle group and the modified prosthetic material Ti-IL4-500 prepared in Example 3.

[0037] Fig. 9 This is a graph showing the results of bone surface porosity analysis under an osteolysis model in which the untreated titanium particle group and the modified prosthetic material Ti-IL4-500 prepared in Example 3 were treated. DETAILED DESCRIPTION

[0038] The following will be combined with the drawings in the embodiments of the present invention to clearly and completely describe the technical solutions in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0039] The present invention discloses a modified metal prosthesis material according to one embodiment, comprising a metal carrier, a vinyl sulfone group covalently connected to the metal carrier, and a therapeutic protein covalently connected to the vinyl sulfone group.

[0040] The material of the metal carrier is titanium or titanium alloy, and the therapeutic protein has an inhibitory effect on osteolysis.

[0041] The modified metal prosthesis material of the present invention covalently links a therapeutic protein that has an inhibitory effect on osteolysis to a metal carrier, so that when the artificial prosthesis made of the modified metal prosthesis material is in the human body, it can promote bone integration and inhibit osteolysis in the early stage, and in the subsequent use process, slowly and continuously release the therapeutic agent, thereby achieving the effect of inhibiting periprosthetic osteolysis, avoiding artificial joint loosening, and extending the service life of the artificial joint.

[0042] It should be pointed out that although there are solutions in the prior art for coating therapeutic proteins on metal prosthesis materials, this solution will cause the therapeutic proteins to be released in a relatively short period of time and is not effective in extending the service life of artificial prostheses.

[0043] Preferably, in this embodiment, the therapeutic protein is covalently linked to the vinyl sulfone group via an amino acid residue.

[0044] Specifically, the amino acid residue includes at least one of -Cys, -Lys and -Hsi.

[0045] Preferably, in this embodiment, the metal carrier is modified with -OH, and the vinyl sulfone group is covalently bonded to the -OH, thereby achieving covalent connection with the metal carrier.

[0046] Preferably, in this embodiment, the therapeutic protein is interleukin-1RA, interleukin-4, interleukin-6, interleukin-10, interleukin-13, transforming growth factor-β1, etc.

[0047] In combination with the specific embodiments, in a particular embodiment, when the therapeutic protein is interleukin-4, the modified metal prosthesis material can play a role in the early stage of implant bone integration by regulating the polarization phenomenon of macrophages, inhibiting the production of osteoclasts and thus inhibiting bone dissolution.

[0048] Preferably, in this embodiment, the metal carrier is in a granular form, and the particle size of the metal carrier is 0.2 μm to 20 μm.

[0049] In other embodiments, the metal carrier may also be designed into other shapes that match human tissue.

[0050] Combination Figure 1 and Figure 2 The present invention discloses a method for preparing the modified metal prosthesis material according to an embodiment of the present invention, comprising the following steps:

[0051] S10, providing a metal carrier, and performing chemical functionalization treatment on the metal carrier.

[0052] Wherein, the material of the metal carrier is titanium or titanium alloy.

[0053] Preferably, the operation of chemically functionalizing the metal support is: placing the metal support in a 0.1M to 5M NaOH solution and treating at 50° C. to 80° C. for 12 h to 48 h.

[0054] The purpose of the above operation is to modify the -OH group on the surface of the metal support, so as to facilitate the subsequent reaction of the -OH group with vinyl sulfone and form a covalent connection.

[0055] After the metal support is chemically functionalized, it is necessary to clean the metal support with double distilled water.

[0056] Generally speaking, before the metal support is subjected to chemical functionalization treatment, the metal support needs to be cleaned. The cleaning operation can be: placing the metal support in 70% acetone, anhydrous ethanol and deionized water for 15 minutes of ultrasonic treatment to remove residual impurities on the surface, and finally drying.

[0057] S20, dispersing the chemically functionalized metal support obtained in S10 into an organic solvent, then adding vinyl sulfone and a catalyst, fully reacting under stirring, and obtaining a semi-finished product after separation.

[0058] The semi-finished product comprises a metal carrier and a vinyl sulfone group covalently connected to the metal carrier.

[0059] Preferably, in S20, the ratio of the chemically functionalized metal support, the organic solvent, the vinyl sulfone and the catalyst is 0.05 g to 0.5 g: 2.5 mL to 10 mL: 0.25 mL to 2.5 mL: 0.05 mmol to 0.5 mmol.

[0060] Preferably, in this embodiment, the organic solvent is acetonitrile.

[0061] Preferably, in this embodiment, the catalyst is triphenylphosphine.

[0062] Preferably, in S20, the sufficient reaction under stirring is specifically: 700 rpm, 25° C., 12 h.

[0063] After separation, the semi-finished product is obtained, and it is necessary to wash the semi-finished product with an organic solvent and ultrapure water in turn.

[0064] S30, dispersing the semi-finished product obtained in S20 into an aqueous solvent, adding a therapeutic protein, and fully reacting under stirring, and obtaining the desired modified metal prosthesis material after separation.

[0065] The modified metal prosthesis material includes a metal carrier, a vinyl sulfone group covalently linked to the metal carrier, and a therapeutic protein covalently linked to the vinyl sulfone group, and the therapeutic protein has an inhibitory effect on osteolysis.

[0066] Preferably, in S30, the ratio of the semi-finished product to the therapeutic protein is 0.01 g to 0.5 g: 0.05 μg to 250 μg.

[0067] Preferably, in this embodiment, the aqueous solvent is a phosphate buffer solution.

[0068] Preferably, in S30, the sufficient reaction under stirring is specifically: 700 rpm, 25° C., 12 h.

[0069] After separation, the desired modified metal prosthesis material is obtained, and the modified metal prosthesis material needs to be cleaned with phosphate buffer, ultrapure water and phosphate buffer in sequence.

[0070] The cleaned modified metal prosthesis material can be dispersed in phosphate buffer for storage.

[0071] The present invention also discloses an embodiment of an artificial prosthesis comprising the modified metal prosthesis material.

[0072] Specifically, the artificial prosthesis can be a bone prosthesis or a dental implant prosthesis.

[0073] The following are specific examples. In the specific examples, titanium particles were purchased from Alfa Aesar Chemical Co., Ltd., vinyl sulfone and TRAP staining solution were purchased from Sigma, fetal bovine serum and α-MEM culture medium were purchased from Gibco, triphenylphosphine was purchased from McLean, IL-4, BSA, amphotericin, tissue fixative and Triton X-100 were purchased from Solebol, cell culture flasks and culture dishes were purchased from Jet Bio Co., Ltd., nuclear transcription factor-κB receptor activating factor ligand and macrophage colony stimulating factor were purchased from Peprotech, and CTSK primary antibody, secondary antibody, phalloidin and DAPI were purchased from Abcam.

[0074] Example 1

[0075] Combination Figure 2 , the preparation process of the embodiment is as follows.

[0076] 1) Titanium particle cleaning:

[0077] 0.1 g of titanium particles were placed in 70% acetone, anhydrous ethanol and deionized water for 15 min of ultrasound to remove residual impurities on the surface of the titanium particles. The supernatant was discarded by centrifugation and the titanium particles were retained and dried.

[0078] 2) Chemical functionalization treatment:

[0079] The cleaned and dried titanium particles were placed in 2.5M NaOH and treated in an 80°C oil bath for 24 hours. The separated chemically functionalized titanium particles were washed with double distilled water and centrifuged to discard the supernatant and retain the titanium particles.

[0080] 3) Surface treatment:

[0081] The titanium particles after chemical functionalization treatment were dispersed in 5 mL of acetonitrile, and 0.5 mL of vinyl sulfone (DVS) and 0.1 mmol of catalyst triphenylphosphine (PPh3) were added. The reaction was carried out at 700 rpm and 25 °C for 12 h. After separation of the semi-finished product, it was washed with acetonitrile and then with ultrapure water. The supernatant was discarded by centrifugation to retain the titanium particles.

[0082] 4) Covalently linked therapeutic proteins:

[0083] Disperse the semi-finished product obtained in the previous step in 5 ml of PB solution, draw out 0.5 ml after mixing and place in sterile EP tubes, add IL-4 solution until the concentration of IL-4 is 0.5 μg / mL, 700 rpm, 25 ° C, react for 12 hours, separate the modified prosthetic material, wash with PB solution, then wash with ultrapure water, and finally wash with a large amount of PBS, and disperse the washed modified prosthetic material in PBS, named Ti-IL4-25.

[0084] Example 2

[0085] The steps of Example 2 are basically the same as those of Example 1, with the only difference being 4) covalently linking the therapeutic protein.

[0086] 4) Covalently linked therapeutic proteins:

[0087] Disperse the semi-finished product obtained in the previous step in 5 ml of PB solution, draw out 0.5 ml after mixing and place in sterile EP tubes, add IL-4 solution until the concentration of IL-4 is 2.5 μg / mL, 700 rpm, 25 ° C, react for 12 hours, separate the modified prosthetic material, wash with PB solution, then wash with ultrapure water, and finally wash with a large amount of PBS, and disperse the washed modified prosthetic material in PBS, named Ti-IL4-125.

[0088] Example 3

[0089] The steps of Example 3 are basically the same as those of Example 1, with the only difference being 4) covalently linking the therapeutic protein.

[0090] 4) Covalently linked therapeutic proteins:

[0091] Disperse the semi-finished product obtained in the previous step in 5 ml of PB solution, mix well and draw out 0.5 ml and place in sterile EP tubes, add IL-4 solution until the concentration of IL-4 is 10 μg / mL, 700 rpm, 25 ° C, react for 12 hours, separate the modified prosthetic material, wash with PB solution, then wash with ultrapure water, and finally wash with a large amount of PBS, and disperse the cleaned modified prosthetic material in PBS and name it Ti-IL4-500.

[0092] Test Case

[0093] 1. Isolation of Mouse Bone Marrow Macrophages

[0094] 1.1) BALB / c mice (male, 6-8 weeks old, purchased from Guangdong Animal Experiment Center) were killed by cervical dislocation and immersed in a beaker containing 75% (v / v) alcohol for 5 min;

[0095] 1.2) Take out the mouse and place it on the workbench. Use surgical instruments to peel the skin, cut off the limbs, and remove the muscle tissue wrapped around the femur;

[0096] 1.3) Place the femur in a PBS solution containing 2.5 mg / L amphotericin;

[0097] 1.4) Enter the intercellular space, prepare 20-30 mL of α-MEM culture medium, cut both ends of the bone with scissors, draw up the culture medium with a 20 mL syringe, and then change the syringe needle to a 1 mL one to flush the bone cavity into a 50 mL centrifuge tube.

[0098] 1.5) Use a pipette to mix the cells flushed out of the bone cavity, filter the cell flushing solution through a 70 / 100 μm filter, transfer it to another 50 mL centrifuge tube, and centrifuge it at 1500 rpm for 5 minutes;

[0099] 1.6) Discard the supernatant and add α-MEM medium containing 10% fetal bovine serum to mix the centrifuged cells;

[0100] 1.7) After counting the cells, 4×10 6 The cells were spread in a cell culture dish with a diameter of 10 cm, and macrophage colony stimulating factor (M-CSF 30 ng / mL) was added for continued culture. The adherent cells obtained subsequently were primary bone marrow macrophages.

[0101] 2. In vitro cell experiment

[0102] 2.1) Digest and count the bone marrow-derived macrophages whose cell density has reached 90%;

[0103] 2.2) Bone marrow-derived macrophages were cultured at a rate of 2×10 4 / cm 2 The cells were inoculated at a density of 100 μg / cm2 on a 48-well plate, with 0.5 mL of culture medium in each well, and divided into five groups, namely, the Ti group (untreated titanium particles, positive control), the Ti+IL4 group (untreated titanium particles + cytokine IL4, negative control group), the modified prosthetic material Ti-IL4-25 prepared in Example 1, the modified prosthetic material Ti-IL4-125 prepared in Example 2, and the modified prosthetic material Ti-IL4-500 prepared in Example 3, and cultured in a 37°C incubator for 8 h to restore the cell state;

[0104] 2.3) The culture medium was replaced, titanium particles and therapeutic drugs were added according to the groups, and nuclear transcription factor-κB receptor activator ligand (RANKL 50 ng / mL) and macrophage colony stimulating factor (M-CSF 30 ng / mL) were added to each group to treat the cells. The medium was replaced every two days until osteoclasts were observed in some groups.

[0105] 3. Osteoclast Identification

[0106] 3.1) TRAP staining (TRAP staining of cells)

[0107] When osteoclasts are formed on the well plate, fix them with tissue fixative at 4°C for 30s-180s. Aspirate the fixative, rinse three times with PBS, add 0.5% (v / v) Triton X-100 to permeabilize for 10 minutes, and rinse once with PBS. Add TRAP staining solution and incubate in a 37°C incubator for 15 minutes. Observe under an optical microscope to obtain Figure 3Among them, the cells with purple or purple-red cytoplasm are osteoclasts.

[0108] 3.2) CTSK immunostaining (CTSK staining of cells)

[0109] When osteoclasts appear, use tissue fixative to fix the cells for 15 minutes and wash them three times with PBS. Then use 0.5% (v / v) Triton X-100 for permeabilization and wash once. Add PBS solution containing 1wt% BSA and incubate at room temperature for 30 minutes. Discard the PBS solution and directly add CTSK primary antibody (volume ratio 1:200) and incubate at 4°C overnight. After washing three times, add Fluor 568-labeled secondary antibody (volume ratio 1:200) and incubate at room temperature for 60 minutes. After washing, add Fluor 488-labeled phalloidin (volume ratio 1:200) and incubate at room temperature for 20 minutes; wash again with PBS solution, and finally add DAPI (volume ratio 1:1000) and incubate at room temperature for 10 minutes. After washing, observe and take pictures under a fluorescence microscope immediately to obtain Figure 4 .

[0110] 3.3) Collecting culture medium for quantitative detection of TRAP activity

[0111] The culture medium after osteoclast induction was collected and stored in a 0.5 mL centrifuge tube at -20°C. TRAP activity was detected on the collected samples according to the instructions of the TRAP activity detection kit (purchased from the source leaf). Finally, the OD value was detected at 410 nm using an enzyme reader, and the data was analyzed using Excel to obtain Figure 5 .

[0112] 4. In vivo mouse skull osteolysis model to investigate the effect of modified material TI-IL4 on periprosthetic osteolysis

[0113] Combined with the in vitro experimental results in the test case, Ti-IL4-500 ng / mg in the modified material group was selected for further in vivo verification. First, the BALB / C male mice were anesthetized, and then the skin of the mouse skull was incised in the middle, the periosteum was cut, the pretreated particles (20 mg / 50 μl) were injected subcutaneously, and then the skin was carefully sutured. This study was mainly divided into 2 groups (8 mice in each group), and the main groupings were as follows: the first group was the model group (titanium particle group), that is, a titanium particle-induced skull osteolysis model was established in the mouse skull; the second group was the modified prosthetic material Ti-IL4-500 treatment group in Example 3. The mice were raised for two weeks after surgery and the samples were collected. The mouse skull specimens were fixed with tissue fixative and then subjected to Micro-CT detection.

[0114] 5. Results

[0115] 5.1) Modified material Ti-IL4 can significantly inhibit osteoclastogenesis

[0116] By TRAP staining ( Figure 3 )、Immunostaining( Figure 4 ), TRAP activity quantification ( Figure 5 ) showed that osteoclast formation occurred in the untreated titanium particle group, while osteoclast formation was significantly reduced in the three groups treated with modified prosthetic material Ti-IL4, and the inhibitory effect was concentration-dependent. There was no significant difference between the Ti-IL4-500 group and the control group with added cytokine IL4.

[0117] 5.2) The modified material Ti-IL4 can significantly inhibit titanium particle-induced skull osteolysis

[0118] Reconstructed by CT scan of mouse skull ( Figure 6 ), bone density ( Figure 7 ), bone volume fraction ( Figure 8 ) and porosity ( Fig. 9 ) analysis, it was found that the modified material Ti-IL4 can inhibit skull osteolysis induced by titanium particles.

[0119] 6. Results

[0120] In summary, the modified material Ti-IL4 can inhibit osteoclastogenesis and has a certain preventive and therapeutic effect on periprosthetic bone dissolution.

[0121] The above-mentioned embodiments only express several implementation methods of the present invention, and the description thereof is relatively specific and detailed, but it cannot be understood as limiting the scope of the patent application. It should be pointed out that, for a person of ordinary skill in the art, several variations and improvements can be made without departing from the concept of the present invention, and these all belong to the protection scope of the present invention. Therefore, the protection scope of the patent of the present invention shall be subject to the attached claims.

Claims

1. A modified metal prosthesis material, It is characterized in that comprising a metal carrier, a vinyl sulfone group covalently linked to the metal carrier, and a therapeutic protein covalently linked to the vinyl sulfone group; The therapeutic protein is covalently linked to the vinyl sulfone group via an amino acid residue; The amino acid residues include at least one of -Cys, -Lys and -Hsi; The metal carrier is modified with -OH, and the vinyl sulfone group is covalently bonded to -OH, thereby achieving covalent connection with the metal carrier; The therapeutic protein is selected from at least one of interleukin-1RA, interleukin-4, interleukin-6, interleukin-10, interleukin-13 and transforming growth factor-β1; The material of the metal carrier is titanium or titanium alloy, and the therapeutic protein has an inhibitory effect on periprosthetic bone dissolution.

2. The modified metal prosthesis material according to claim 1, It is characterized in that The modified metal prosthesis is made of titanium or titanium alloy metal material.

3. A method for preparing the modified metal prosthesis material according to claim 1 or 2, It is characterized in that The steps include: Providing a metal carrier, and performing chemical functionalization treatment on the metal carrier, wherein the material of the metal carrier is titanium or a titanium alloy; Dispersing the chemically functionalized metal carrier into an organic solvent, then adding vinyl sulfone and a catalyst, reacting them fully under stirring, and obtaining a semi-finished product after separation, wherein the semi-finished product includes the metal carrier and a vinyl sulfone group covalently connected to the metal carrier; The semi-finished product is dispersed in an aqueous solvent, a therapeutic protein is added, and the mixture is fully reacted under stirring. After separation, the desired modified metal prosthesis material is obtained, wherein the modified prosthesis material includes the metal carrier, the vinyl sulfone group covalently linked to the metal carrier, and the therapeutic protein covalently linked to the vinyl sulfone group, and the therapeutic protein has an inhibitory effect on periprosthetic bone dissolution.

4. The method for preparing the modified prosthetic material according to claim 3, It is characterized in that The operation of chemical functionalization treatment of the metal carrier is as follows: placing the metal carrier in a 0.1M to 5M NaOH solution and treating it at 50° C. to 80° C. for 12 h to 48 h.

5. The method for preparing the modified prosthetic material according to claim 3, It is characterized in that The chemically functionalized metal support is dispersed in an organic solvent, and then vinyl sulfone and a catalyst are added, wherein the ratio of the chemically functionalized metal support, the organic solvent, the vinyl sulfone and the catalyst is 0.05 g to 0.5 g: 2.5 mL to 10 mL: 0.25 mL to 2.5 mL: 0.05 mmol to 0.5 mmol; The organic solvent is acetonitrile, and the catalyst is triphenylphosphine; Dispersing the semi-finished product in an aqueous solvent and adding the therapeutic protein, the ratio of the semi-finished product to the therapeutic protein is 0.05 g to 0.5 g: 25 μg to 250 μg; The aqueous solvent is phosphate buffer.

6. An artificial prosthesis, It is characterized in that The artificial prosthesis comprises the modified prosthesis material according to claim 1 or 2.